Literature DB >> 26830041

Antidiabetic and hypolipidemic effects of adropinin streoptozotocin-induced type 2 diabetic rats.

R Akcilar, F E Kocak, H Simsek, A Akcilar, Z Bayat, E Ece, H Kokdasgil.   

Abstract

BACKGROUND: To examine the effects of adropin on glucose and lipid metabolism in a rat model of Type 2 diabetes mellitus (T2DM).
METHODS: T2DM were established using high-fat diet and streptozocin (STZ; 35 mg/kg/b.w.). Seven days after STZ induction, diabetic rats were randomly treated with adropin (2.1 μg/kg/day intraperitonealy) for 10 days. The study involved the evaluation of biochemical parameters, including blood glucose, total cholesterol (TC), triglycerides (TG), low-density lipoprotein-cholesterol (LDL-C), high-density lipoprotein-cholesterol (HDL-C), aspartate transaminase (AST), alanine transaminase (ALT), alkaline phosphatase (ALP) and gamma glutamyl transferase (GGT) activities. Additionally, Tumor necrosis factor-alpha (TNF-α), interleukin 6 (IL-6) and inducible nitric oxide synthase (iNOS) mRNA gene expressions in pancreas tissue were determined by reverse transcription-polymerase chain reaction.
RESULTS: The serum levels of insulin and adropin were determined by ELISA. Treatment with adropin showed a significant reduction in blood glucose levels, HbA1c (%), HOMA-IR and increase in HOMA-β, serum insulin levels. In addition, intraperitoneal adropin application can reduce serum levels of TC, TG, LDL-C, and increase level of HDL-C. Adropin also effectively ameliorated the alterations in TNF-α, IL-6 and iNOS mRNA expression.
CONCLUSION: The present study indicates that the adropin possesses antidiabetic and antidyslipidemic effects in T2DM (Tab. 2, Fig. 3, Ref. 32).

Entities:  

Keywords:  adropin; blood glucose; high fat diet.; insulin; type 2 diabetic rat

Mesh:

Substances:

Year:  2016        PMID: 26830041     DOI: 10.4149/bll_2016_020

Source DB:  PubMed          Journal:  Bratisl Lek Listy        ISSN: 0006-9248            Impact factor:   1.278


  14 in total

1.  Low plasma adropin concentrations increase risks of weight gain and metabolic dysregulation in response to a high-sugar diet in male nonhuman primates.

Authors:  Andrew A Butler; Jinsong Zhang; Candice A Price; Joseph R Stevens; James L Graham; Kimber L Stanhope; Sarah King; Ronald M Krauss; Andrew A Bremer; Peter J Havel
Journal:  J Biol Chem       Date:  2019-04-15       Impact factor: 5.157

2.  Serum Adropin Levels Are Reduced in Adult Patients with Nonalcoholic Fatty Liver Disease.

Authors:  Orkide Kutlu; Özgür Altun; Okan Dikker; Şerife Aktaş; Neslihan Özsoy; Yücel Arman; Eylem Özgün Çil; Mustafa Özcan; Şengül Aydın Yoldemir; Murat Akarsu; İlkim Deniz Toprak; Kerem Kırna; Yasin Kutlu; Zeki Toprak; Hasan Eruzun; Tufan Tükek
Journal:  Med Princ Pract       Date:  2019-04-16       Impact factor: 1.927

3.  Association between adropin and coronary artery lesions in children with Kawasaki disease.

Authors:  Maoling Yang; Qiongfei Pei; Jing Zhang; Haobo Weng; Fengchuan Jing; Qijian Yi
Journal:  Eur J Pediatr       Date:  2021-03-13       Impact factor: 3.183

4.  Adropin Contributes to Anti-Atherosclerosis by Suppressing Monocyte-Endothelial Cell Adhesion and Smooth Muscle Cell Proliferation.

Authors:  Kengo Sato; Tomoyuki Yamashita; Remina Shirai; Koichiro Shibata; Taisuke Okano; Maho Yamaguchi; Yusaku Mori; Tsutomu Hirano; Takuya Watanabe
Journal:  Int J Mol Sci       Date:  2018-04-26       Impact factor: 5.923

5.  Antidiabetic, Antihyperlipidemic, Antioxidant, Anti-inflammatory Activities of Ethanolic Seed Extract of Annona reticulata L. in Streptozotocin Induced Diabetic Rats.

Authors:  Wenbin Wen; Yukiat Lin; Zhenyu Ti
Journal:  Front Endocrinol (Lausanne)       Date:  2019-10-23       Impact factor: 5.555

Review 6.  Adropin as A Fat-Burning Hormone with Multiple Functions-Review of a Decade of Research.

Authors:  Mariami Jasaszwili; Maria Billert; Mathias Z Strowski; Krzysztof W Nowak; Marek Skrzypski
Journal:  Molecules       Date:  2020-01-27       Impact factor: 4.411

7.  Association of Serum Adropin Concentrations with Diabetic Nephropathy.

Authors:  Wenchao Hu; Li Chen
Journal:  Mediators Inflamm       Date:  2016-07-28       Impact factor: 4.711

8.  Adropin: An endocrine link between the biological clock and cholesterol homeostasis.

Authors:  Sarbani Ghoshal; Joseph R Stevens; Cyrielle Billon; Clemence Girardet; Sadichha Sitaula; Arthur S Leon; D C Rao; James S Skinner; Tuomo Rankinen; Claude Bouchard; Marinelle V Nuñez; Kimber L Stanhope; Deborah A Howatt; Alan Daugherty; Jinsong Zhang; Matthew Schuelke; Edward P Weiss; Alisha R Coffey; Brian J Bennett; Praveen Sethupathy; Thomas P Burris; Peter J Havel; Andrew A Butler
Journal:  Mol Metab       Date:  2017-12-30       Impact factor: 7.422

9.  Plasma Adropin as a Potential Marker Predicting Obesity and Obesity-associated Cancer in Korean Patients With Type 2 Diabetes Mellitus.

Authors:  Ha-Neul Choi; Jung-Eun Yim
Journal:  J Cancer Prev       Date:  2018-12-30

10.  Assessment of Serum Concentrations of Adropin, Afamin, and Neudesin in Children with Type 1 Diabetes.

Authors:  Agnieszka Polkowska; Izabela Elżbieta Pasierowska; Marta Pasławska; Elżbieta Pawluczuk; Artur Bossowski
Journal:  Biomed Res Int       Date:  2019-10-24       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.